Half a year of treatment with a high dose of omega-3 acid ethyl ester (Lovaza, GlaxoSmithKline) in patients with a recent MI surpassed placebo in mitigating adverse cardiac remodeling.
The Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction (OMEGA-REMODEL) trial by Dr Bobak Heydari (Brigham and Women's Hospital, Boston, MA) and colleagues was published in the August 2, 2016 issue of Circulation. It was presented in preliminary form at a meeting last year and covered by heartwire from Medscape at the time.
The trial randomized 358 patients who had had a recent heart attack to receive placebo or 4 mg/day of Lovaza plus standard care for 6 months. Patients who received the study drug had a lower adverse left ventricular end systolic volume index (LVESVI; an indication of the heart's pumping ability), less myocardial scarring (fibrosis) in the undamaged areas of the heart, and better levels of some serum biomarkers.
On average, patients who received the fish-oil capsules experienced about a 6% improvement in heart pumping function and about a 6% suppression of fibrosis. However, patients whose red blood cell levels of omega-3 fatty acid were in the highest quartile had a 13% improvement in heart pumping function, suggesting a dose-response relationship. There were also no major adverse effects.